A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

UNDATED (WKRC) - Weight-loss medications may not be as effective in "real-world" settings as they are in clinical trials, ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.

Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...

UNDER EMBARGO UNTIL Tuesday, June 10, 2025, 3 a.m. EDT, CLEVELAND: A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...